Dr. Patrick Meyer, Global Head of Business Development at Rentschler Biopharma, outlines the deciding factors biotechs should consider when selecting a contract development and manufacturing organization (CDMO) partner.
Sponsored by Rentschler Biopharma
Dr. Patrick Meyer, Global Head of Business Development at Rentschler Biopharma, explores what biotech companies should prioritize when evaluating a CDMO partnership. He emphasizes that the decision carries long-term consequences given projects typically span many years. Key criteria discussed include transparent communication, accurate timelines, and a proven track record of guiding complex molecules through to commercialization. Also, he addresses the importance of technical expertise and supply chain reliability, noting that not all CDMOs are equipped to handle challenging molecules from the outset. Company stability, organizational size, and the depth of client engagement can factor into a biotech's selection process.
